Watson challenges patent on cancer drug Velcade

Published: 03:20:59 PM, Fri 28 December 2012 UTC

PARSIPPANY, N.J. (AP) — Watson Pharmaceuticals is challenging the patent on a bone marrow cancer drug made by Millennium Pharmaceuticals.

Watson's Actavis division asked the Food and Drug Administration to approve a generic version of the drug Velcade, which is used to treat multiple myeloma. One of the companies that markets the drug has filed a patent infringement lawsuit against Watson, and as a result, the FDA won't approve Watson's generic for 30 months, or until the litigation is resolved.

Watson said U.S. sales of Velcade, or bortezomib, totaled $740 million over the 12 months ended Oct. 31. The drug is marketed in the U.S. by Millennium, a unit of Japanese drugmaker Takeda. Johnson & Johnson sells Velcade in other markets. Watson said Millennium filed the patent infringement lawsuit.

Shares of Watson Pharmaceuticals Inc. rose 5 cents to $89.26 in morning trading.

Tags: johnson, food and drug administration, watson pharmaceuticals inc., fda, watson pharmaceuticals, watson, millennium pharmaceuticals, velcade, law_crime, cents, drug administration, oct., n.j., result, generic version, companies, parsippany, morning trading, food, osteoporosis, patent infringement lawsuit, u.s. sales, litigation, multiple myeloma, bone marrow cancer, bone marrow, thalidomide, lenalidomide, bortezomib, japanese drugmaker takeda, drug velcade, cancer drug velcade, actavis division, proteasome